Rexahn Pharmaceuticals, Inc. (REXN)

Our Portfolio

RX-3117

Innovative nucleoside analogue targeted to cancer cells

RX-3117 is a novel, oral, small molecule nucleoside prodrug which is activated (phosphorylated) by UCK2, a kinase that is predominantly expressed in cancer cells. Once activated within the cancer cell, RX-3117 is incorporated into the DNA or RNA inducing apoptotic death of tumor cells.

View RX-3117

RX-5902

First-in-Class Small Molecule Modulator of the β-catenin/Wnt Pathway

RX-5902 modulates the activity of the β-catenin/Wnt pathway which is a key pathway involved in cancer cell growth and proliferation, oncogene expression and -activation of the immune response to cancer. RX-5902 modulates the pathway through inhibition of phosphorylated p68 which is over-expressed in tumor cells.

View RX-5902

RX-0301

Novel Specific Inhibitor of AKT-1

RX-0301 is an antisense oligonucleotide that inhibits translation of the mRNA responsible for coding Akt-1. Akt-1 is a protein that is associated with cancer cell growth and proliferation and the development of resistance to certain anticancer agents. Akt-1 is over-expressed in multiple forms of cancer including hepatic, renal, breast, colorectal, gastric, pancreatic, prostate and melanoma.

View RX-0301